Intrathecal neostigmine has been used as an adjunct to intrathecal local anaesthetic or opioid to prolong regional analgesia and improve haemodynamic stability, with variable results. This meta-analysis aims to evaluate the effectiveness and side-effects of intrathecal neostigmine in the perioperative and peripartum settings. The literature search was based on Cochrane Controlled Trials Register, EMBASE and MEDLINE (from 1966 to 14 November 2003) databases. Volunteer and animal studies were excluded. We identified 26 studies and 19 were considered suitable for detailed data extraction. Intrathecal neostigmine increased the incidence of nausea and vomiting (OR 5.0, 95% CI: 3.4 to 7.3; P<0.00001), bradycardia requiring intravenous atropine (OR 2.7, 95% CI: 1.4 to 5.4; P=0.005), and anxiety, agitation, or restlessness (OR 10.3, 95% CI: 3.7 to 28.9; P=0.00001). It improved the overall 24 hour VAS score (-1.4 VAS pain score, 95% CI: -1.7 to -1.2, P<0.00001), delayed the time of first request for rescue analgesia (168 min, 95% CI: 125 to 211; P<0.00001), and reduced the total number of rescue injections of nonsteroidal anti-inflammatory drug within the first 24 hours P=0.00001). It did not affect the duration of motor blockade (3.5 min, P=0.17) or the total amount of ephedrine required P=0.5). Adding intrathecal neostigmine to other spinal medications improves perioperative and peripartum analgesia marginally when compared with placebo. It is associated with significant side-effects and the disadvantages outweigh the minor improvement in analgesia achieved. FIGURE 2: Forest plot showing the incidence of nausea and vomiting after treatment with intrathecal neostigmine.
Intrathecal neostigmine inhibits the breakdown of an endogenous spinal neurotransmitter, acetylcholine. It has been shown to produce analgesia on its own 1 and to reduce the risk of hypotension induced by spinal local anaesthetic in animal studies 2, 3 . Both animal and human studies show that intrathecal neostigmine does not affect spinal cord blood flow and does not induce any significant toxic effect in the spinal cord [4] [5] [6] . However, significant systemic sideeffects of intrathecal neostigmine, such as nausea and vomiting, motor blockade, sedation, and hypertension, have been reported, especially with doses greater than 200 µg 5 . A recent systematic review included a small number of randomized controlled trials and could not quantify the potential clinical benefits and side-effects of intrathecal neostigmine 7 . A number of clinical studies, using lower doses of intrathecal neostigmine, have been published since the last review, with variable results regarding its analgesic effect and side-effects. We aimed to reevaluate the use of intrathecal neostigmine as an adjunct in spinal anaesthesia for the prevention and treatment of acute perioperative and peripartum pain. In particular, we wanted to quantify the potential benefits and side-effects of intrathecal neostigmine when used as an adjunct to other intrathecal medications in spinal anaesthesia or analgesia.
MATERIALS AND METHODS
A literature search was based on Cochrane Controlled Trials Register (2003 issue 4), MEDLINE and EMBASE (1996 to 14 November 2003) databases. Only randomized controlled clinical trials or quasi-randomized controlled clinical trials in the perioperative and peripartum settings were included in this meta-analysis. Studies with more than one active component were included if both intervention and control groups were exposed to the other active component. Clinical trials that compared intrathecal neostigmine with another active intervention such as intrathecal morphine but without a separate placebo control group in the same trial were excluded. Trials that involved significant dissimilar co-interventions, such as one group of patients receiving intrathecal local anaesthetic with intrathecal neostigmine and the other group only placebo, were excluded. Volunteer and animal studies were also excluded.
During the electronic database search, the following exploded MeSH terms were used: "neostigmine" and "intrathecal", "subarachnoid", or "spinal". The reference lists of related reviews and identified original articles were checked for relevant trials. Finally, the websites of International Network of Agencies of Health Technology Assessment and International Society of Technology Assessment in Health Care were searched. If necessary, the authors of the identified trials were contacted to obtain additional vital information and unpublished data that were considered important in the data analysis. Studies published in other languages other than English were translated and included in this meta-analysis.
Two independent reviewers examined the titles and the abstracts of all identified trials to confirm they fulfilled the above-defined inclusion criteria. They examined and recorded the trial characteristics and outcomes independently, using a pre-designed article abstraction form. This abstraction form was used to record information regarding the quality of the trial, such as allocation concealment, randomization method, blinding of treatment, inclusion and exclusion criteria. The grading of allocation concealment was based on the Cochrane approach, i.e. adequate or uncertain or clearly inadequate. Any disagreements between the two independent reviewers were resolved by consensus or by a third reviewer if there was no consensus. Articles that fulfilled the inclusion criteria were analysed further for data extraction.
The incidences of nausea and vomiting, bradycardia requiring the use of intravenous atropine, involuntary defaecation, and anxiety, agitation, or restlessness were recorded as categorical variables. The time to request first rescue analgesia, the duration of motor blockade till recovery to Bromage grade 2, the total amount of intravenous ephedrine required, the overall 24-hour visual analogue scale (VAS) pain score, and the total number of intramuscular nonsteroidal anti-inflammatory drug (NSAID) injections in 24 hours, were considered continuous variables and mean and standard deviations extracted and recorded in the data abstraction form. Two reviewers extracted the data independently and the results were checked for consistency. Any duplicate publications were combined to represent one single trial. Data were checked and entered into Review Manager (version 4.1) database by two independent reviewers and the results checked.
Statistical Analysis
The proportion of patients with different sideeffects such as nausea and vomiting, bradycardia requiring the use of intravenous atropine, involuntary defaecation, and anxiety, agitation, or restlessness were reported as odds ratios (OR) with 95% confidence intervals (95% CI), using random effect model. The continuous outcome variables were reported as weighted mean difference (WMD) in the original unit of measurement with 95% CI, using random effect model. If only the median and range were reported in the original studies, but the data were nearly normally distributed, the median would be assigned as the mean and the standard deviation estimated as (0.95×range)/4. The 24-hour VAS pain score was assessed by asking the patient the overall pain control over 24 hours and this ranged from 0 to 10 in most studies. The VAS pain data was reported on a scale of 0 to 5 in one study and the data were converted to a scale of 10. The presence of heterogeneity between trials was assessed by chi-squared test. The extent of inconsistency 8 among results of the trials was assessed by statistics I 2 . Sensitivity analysis, such as excluding poor quality trials (trials with clearly inadequate allocation concealment or blinding of randomization) was conducted to test the robustness of the results. Multiple parallel comparisons in the same study were labelled with the same study identity name followed by either a, b, c, or d in the Forest plots. In order to facilitate the interpretation of any dose response relationship in the effectiveness and side-effect profiles of intrathecal neostigmine, studies were ranked in all the Forest plots according to the dose of intrathecal neostigmine used, with the study using the highest dose of intrathecal neostigmine at the top of the plots. Publication bias was assessed by funnel plot.
RESULTS
We identified 26 human studies involving the use of intrathecal neostigmine and 19 were considered suitable for detailed data extraction. Among the seven studies that were excluded, three were volunteer studies [9] [10] [11] , one study did not use a control group 12 , one study used a different co-intervention between the neostigmine group and control group 13 , one study did not assess any outcome of interest included in this meta-analysis 14 , and one study did not use randomization in the study (Figure 1) 15 . There was no difference in the assessment of studies, suitability for inclusion and only minor differences in data extraction between the two investigators. The minor differences in data extraction were resolved after carefully examining the studies together.
Twelve studies compared spinal local anaesthetic with intrathecal neostigmine or placebo. Two studies involved concurrent intrathecal clonidine, opioid and local anaesthetic in both the neostigmine and control groups 16, 17 . One study involved general anaesthesia and intrathecal morphine in both the neostigmine and control groups 18 . Two studies used concurrent intrathecal opioid and spinal local anaesthetic in both the neostigmine and control groups 19, 20 . One study involved concurrent intrathecal clonidine and local anaesthetic in both the neostigmine and control groups 21 . One study made three parallel comparisons involving intravenous placebo, intravenous fentanyl or intravenous ketamine in both the neostigmine and control groups 22 . Across all studies, ten different doses of intrathecal neostigmine, ranging from 1 to 500 µg, were used. Seven studies assessed more than one dose of intrathecal neostigmine 18, 19, [23] [24] [25] [26] [27] . In addition, three other studies involved more than one active treatment group, with different concurrent treatments in different active treatment groups and a comparable control group for each different active treatment group [20] [21] [22] .
Nine studies involved patients undergoing gynaecologic procedures [18] [19] [20] 22, [27] [28] [29] [30] [31] , two studies involved parturients undergoing elective caesarean delivery 21, 32 , two studies assessed intrathecal neostigmine for labour analgesia 16, 17 , three studies involved patients undergoing lower limb orthopaedic operations 25 general surgical operations in the lower abdomen or perineum [23] [24] [25] . All except one study involved patients with mean age less than 60 years old. Allocation concealment was clearly adequate in 10 studies. Eighteen studies were in English and one in Turkish. All studies used ephedrine as the vasopressor for hypotension when a predefined end-point was reached and fluid hydration was a bolus before spinal anaesthesia, with or without a fixed infusion rate as maintenance. The details of all included studies are described in Appendix 1.
The results of all the categorical outcome variables were homogenous. Intrathecal neostigmine significantly increased the incidence of nausea and vomiting (OR 5.0, 95% CI: 3.4 to 7.3; P<0.00001, I 2 =16%), bradycardia requiring intravenous atropine (OR 2.7, 95% CI: 1.4 to 5.4; P=0.005, I 2 =0%), and anxiety, agitation, or restlessness (OR 10.3, 95% CI: 3.7 to 28.9; P=0.00001, I 2 =0%). There was a trend toward an increased rate of faecal incontinence after intrathecal neostigmine (OR 3.0, 95% CI: 0.9 to 10.5, P=0.08, I 2 =0%). No obvious dose dependent relationship in the categorical outcome variables was observed when the trend of mean odds ratios was assessed in each forest plot (Figures 2-5 ).
Adding intrathecal neostigmine to other spinal medications improved the overall 24-hour VAS score (-1.4 VAS pain score, 95% CI: -1.7 to -1.2, P<0.00001, I 2 =0%), delayed the time of first request for rescue analgesia (168 min, 95% CI: 125 to 211; P<0.00001, I 2 =97%), but only slightly reduced the total number of rescue NSAID injections required within the first 24 hours (-0.8, 95%CI: -1.1 to -0.4; P=0.00001, I 2 =90%) ( Figures 6-8 ). Intrathecal neostigmine did not increase the duration of motor blockade (3.5 min, 95% CI: -1.5 to 8.6; P=0.17, I 2 =11%) and did not reduce the total amount of ephedrine required to maintain haemodynamic stability intraoperatively (-0.4 mg, 95%CI: -1.5 to 0.7; P=0.5, I 2 =0%).
Subgroup analysis of studies involving only parturients receiving intrathecal neostigmine for elective caesarean delivery or labour analgesia showed a similar trend in the results. Intrathecal neostigmine increased the incidence of nausea and vomiting (OR 16.1, 95% CI: 7.1 to 36.8; P<0.00001, I 2 =0%), and anxiety, agitation, or restlessness (OR 5.5, 95% CI: 0.9 to 33.3; P=0.07, I 2 =0%). It delayed the time of first request for rescue analgesia (179 min, 95% CI: 55 to 303; P=0.005, I 2 =98.5%), but did not increase the duration of motor blockade (54 min, 95% CI: -16 to 123; P=0.13, I 2 =73.2%) and did not reduce the total amount of ephedrine required to maintain haemodynamic stability (-0.4 mg, 95% CI: -5.2 to 5.9; P=0.9, I 2 =55.9%).
Sensitivity analysis by excluding studies with unclear allocation concealment did not change the direction and the magnitude of the results significantly. After excluding 9 studies with unclear allocation concealment, the odds ratio of the incidence of nausea and vomiting was 3.1 (95% CI: 1.9-5.0; P<0.0001, I 2 =13.5%), bradycardia was 2.8 (95% CI: 1.2-6.7; P=0.04, I 2 =0%), faecal incontinence was 2.1 (95% CI: 0.5 to 9.3; P=0.3, I 2 =0%), and anxiety or restlessness or agitation was 8.6 (95% CI: 2.2 to 24.3; P=0.02, I 2 =0%) after intrathecal neostigmine. The overall 24-hour VAS pain score was -1.4 (95% CI: -1.7 to -1.1; P<0.0001, I 2 =13.9%), the time of first request for analgesia 200 min (95% CI: 145 to 256; P<0.0001, I 2 =96.5%), the total number of NSAID injections was -0.8 (95% CI: -1.2 to 0.4; P=0.0003, I 2 =90.8%), the total amount of ephedrine required was 0.5 mg (95% CI: -2.0 to 1.0; P=0.4, I 2 =0%), and the increase in duration of motor block was 1.6 min (95% CI: -5.7 to 8.8; P=0.93, I 2 =0%) after intrathecal neostigmine. There was a small publication bias in this meta-analysis as demonstrated by the funnel plot ( Figure 9 ), and small studies with severe nausea and vomiting after intrathecal neostigmine seemed less likely to be published. No pharmacoeconomic analysis was done in any of the included studies.
DISCUSSION
There was a good consistency in most outcomes of the studies included in this meta-analysis. Heterogeneity was observed only in two continuous outcome variables, the total number of rescue NSAID injections required in 24 hours and the time to request first rescue analgesia. By examining the mean difference between treatment and control group of each study down the forest plots, we could not observe any obvious dose dependent relationship in these two continuous outcome variables. The differences in intrathecal neostigmine dose are therefore unlikely to account for the heterogeneity. However, there was 
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07 Total amount of vasopressor required (mg) 08 Duration of effective analgesia significant variability, with large standard deviations in the results of each individual study in these two continuous outcome variables. Wide individual variations in the pain threshold and hence requirement for supplementary analgesia within the first 24 hours of surgery appears the most likely explanation. Also, the variety of surgical procedures in the analysis could be reflected in this heterogeneity. Intrathecal neostigmine has been shown to be more effective in improving analgesia in the acute postoperative period 35 , and thus we excluded volunteer studies from this meta-analysis. Nevertheless, the improvement in analgesia after adding intrathecal neostigmine to other spinal medications in the perioperative and peripartum settings was very small. While intrathecal neostigmine has been shown to have additive analgesic effect with NSAID in animal studies 36 , our results did not demonstrate a dramatic reduction in NSAID consumption after intrathecal neostigmine. For the doses of intrathecal neostigmine (500 µg or less) examined in this meta-analysis, we also did not confirm the belief that intrathecal neostigmine improves haemodynamic stability when used with either intrathecal local anaesthetic or clonidine [2] [3] [4] 37 . On the other hand, the increase in frequency of side-effects after intrathecal neostigmine was very significant. Many of these side-effects did not seem to be dose dependent and occurred even when the dose of intrathecal neostigmine was as low as 5 to 10 µg 9, 16, 17, 19 . Furthermore, nausea and vomiting induced by intrathecal neostigmine was reported to be severe, repetitive, prolonged, and resistant to prevention or treatment by antiemetic drugs (such as metoclopramide, promethazine, ondansetron, droperidol, and dexamethasone) 9, 17, 24, 26, 34, 38 . With the large sample size of this meta-analysis, we also noted some less well described side-effects of intrathecal neostigmine. Even low doses 26 appeared to increase the risk of agitation, restlessness and faecal incontinence, the latter being disturbing if the operative field was contaminated. Other unpleasant side-effects such as sweating above the level of the sensory block and intensive salivation were also observed in a few studies 18, 23, 29, 33 .
No pharmacoeconomic analysis was performed in any of the studies included in this meta-analysis. Improvement in perioperative analgesia by intrathecal neostigmine may reduce the requirement for rescue analgesics and thus reduce drug costs. However, side-effects of intrathecal neostigmine such as severe nausea and vomiting may require multiple antiemetic drugs and treatments, and delay recovery room discharge 9 . Based on the frequency and severity of side-effects associated with intrathecal neostig-mine and the relatively minor improvements in analgesia, intrathecal neostigmine is unlikely to be costeffective as an adjunct to other spinal medications. In contrast to intrathecal neostigmine, epidural neostigmine has been shown to improve labour analgesia and postoperative analgesia without many sideeffects 39, 40 and the use of epidural neostigmine in other clinical scenarios deserves further investigation.
Meta-analysis, as with any overview, is prone to bias. In order to avoid selection bias, we used three databases for the literature search and included studies written in different languages. Sensitivity analysis by excluding studies with unclear allocation concealment also did not change the direction and the magnitude of the results significantly. We thus believe that this meta-analysis provides a reliable overall picture of the effectiveness and side-effect profile of intrathecal neostigmine in acute pain settings.
In conclusion, adding intrathecal neostigmine to other spinal medications improves perioperative and peripartum analgesia only marginally when compared with placebo. It is associated with significant sideeffects such as nausea and vomiting, bradycardia requiring atropine treatment, and anxiety, agitation or restlessness. The significant increase in side-effects outweighs the minor improvements in analgesia achieved by adding intrathecal neostigmine to other spinal medications. The routine use of intrathecal neostigmine as an adjunct to other spinal medications, to improve analgesia in the perioperative and peripartum setting, is not recommended.
